Betsy E Castro1, Maritza Berrio2, Monica L Vargas1, Lina P Carvajal1, Lina V Millan1, Rafael Rios1, Angie K Hernandez1, Sandra Rincon1, Paola Cubides1, Erika Forero1, An Dinh3, Carlos Seas4, Jose M Munita3,5,6, Cesar A Arias1,3,7,8, Jinnethe Reyes1,3, Lorena Diaz1,3,6. 1. Molecular Genetics and Antimicrobial Resistance Unit, International Center for Microbial Genomics, Universidad El Bosque, Bogotá, Colombia. 2. Instituto Nacional de Salud, Bogotá, Colombia. 3. Center for Antimicrobial Resistance and Microbial Genomics, McGovern Medical School, University of Texas Health Science Center, Houston, Texas, USA. 4. Universidad Peruana Cayetano Heredia, Lima, Peru. 5. Genomics and Resistant Microbes (GeRM) Group, Clínica Alemana de Santiago, Universidad del Desarrollo School of Medicine, Santiago, Chile. 6. Millennium Initiative for Collaborative Research On Bacterial Resistance (MICROB-R), Santiago, Chile. 7. Division of Infectious Diseases, Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center, Houston, Texas, USA. 8. Center for Infectious Diseases, School of Public Health, University of Texas McGovern Medical School at Houston, Houston, Texas, USA.
Abstract
BACKGROUND: Vancomycin is a common first-line option for MRSA infections. The heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) phenotype is associated with therapeutic failure. However, hVISA isolates are usually reported as vancomycin susceptible by routine susceptibility testing procedures. OBJECTIVES: To detect and characterize the hVISA phenotype in MRSA isolates causing infections in nine Latin American countries. METHODS: We evaluated a total of 1189 vancomycin-susceptible MRSA isolates recovered during 2006-08 and 2011-14. After an initial screening of hVISA using glycopeptide-supplemented agar strategies, the detection of hVISA was performed by Etest (GRD) and Macro-method (MET). Isolates deemed to be hVISA were subjected to population analysis profile/AUC (PAP/AUC) and WGS for further characterization. Finally, we interrogated alterations in predicted proteins associated with the development of the VISA phenotype in both hVISA and vancomycin-susceptible S. aureus (VSSA) genomes. RESULTS: A total of 39 MRSA isolates (3.3%) were classified as hVISA (1.4% and 5.6% in MRSA recovered from 2006-08 and 2011-14, respectively). Most of the hVISA strains (95%) belonged to clonal complex (CC) 5. Only 6/39 hVISA isolates were categorized as hVISA by PAP/AUC, with 6 other isolates close (0.87-0.89) to the cut-off (0.9). The majority of the 39 hVISA isolates exhibited the Leu-14→Ile (90%) and VraT Glu-156→Gly (90%) amino acid substitutions in WalK. Additionally, we identified 10 substitutions present only in hVISA isolates, involving WalK, VraS, RpoB and RpoC proteins. CONCLUSIONS: The hVISA phenotype exhibits low frequency in Latin America. Amino acid substitutions in proteins involved in cell envelope homeostasis and RNA synthesis were commonly identified. Our results suggest that Etest-based methods are an important alternative for the detection of hVISA clinical isolates.
BACKGROUND:Vancomycin is a common first-line option for MRSA infections. The heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) phenotype is associated with therapeutic failure. However, hVISA isolates are usually reported as vancomycin susceptible by routine susceptibility testing procedures. OBJECTIVES: To detect and characterize the hVISA phenotype in MRSA isolates causing infections in nine Latin American countries. METHODS: We evaluated a total of 1189 vancomycin-susceptible MRSA isolates recovered during 2006-08 and 2011-14. After an initial screening of hVISA using glycopeptide-supplemented agar strategies, the detection of hVISA was performed by Etest (GRD) and Macro-method (MET). Isolates deemed to be hVISA were subjected to population analysis profile/AUC (PAP/AUC) and WGS for further characterization. Finally, we interrogated alterations in predicted proteins associated with the development of the VISA phenotype in both hVISA and vancomycin-susceptible S. aureus (VSSA) genomes. RESULTS: A total of 39 MRSA isolates (3.3%) were classified as hVISA (1.4% and 5.6% in MRSA recovered from 2006-08 and 2011-14, respectively). Most of the hVISA strains (95%) belonged to clonal complex (CC) 5. Only 6/39 hVISA isolates were categorized as hVISA by PAP/AUC, with 6 other isolates close (0.87-0.89) to the cut-off (0.9). The majority of the 39 hVISA isolates exhibited the Leu-14→Ile (90%) and VraT Glu-156→Gly (90%) amino acid substitutions in WalK. Additionally, we identified 10 substitutions present only in hVISA isolates, involving WalK, VraS, RpoB and RpoC proteins. CONCLUSIONS: The hVISA phenotype exhibits low frequency in Latin America. Amino acid substitutions in proteins involved in cell envelope homeostasis and RNA synthesis were commonly identified. Our results suggest that Etest-based methods are an important alternative for the detection of hVISA clinical isolates.
Authors: Anton Bankevich; Sergey Nurk; Dmitry Antipov; Alexey A Gurevich; Mikhail Dvorkin; Alexander S Kulikov; Valery M Lesin; Sergey I Nikolenko; Son Pham; Andrey D Prjibelski; Alexey V Pyshkin; Alexander V Sirotkin; Nikolay Vyahhi; Glenn Tesler; Max A Alekseyev; Pavel A Pevzner Journal: J Comput Biol Date: 2012-04-16 Impact factor: 1.479
Authors: Susan Boyle-Vavra; Shouhui Yin; Dae Sun Jo; Christopher P Montgomery; Robert S Daum Journal: Antimicrob Agents Chemother Date: 2012-10-15 Impact factor: 5.191
Authors: Flávia Rossi; Lorena Diaz; Aye Wollam; Diana Panesso; Yanjiao Zhou; Sandra Rincon; Apurva Narechania; Galen Xing; Thais S R Di Gioia; André Doi; Truc T Tran; Jinnethe Reyes; Jose M Munita; Lina P Carvajal; Alejandra Hernandez-Roldan; Denise Brandão; Inneke Marie van der Heijden; Barbara E Murray; Paul J Planet; George M Weinstock; Cesar A Arias Journal: N Engl J Med Date: 2014-04-17 Impact factor: 91.245
Authors: Sabrina Di Gregorio; Beatriz Perazzi; Andrea Martinez Ordoñez; Stella De Gregorio; Monica Foccoli; María Beatriz Lasala; Susana García; Carlos Vay; Angela Famiglietti; Marta Mollerach Journal: Microb Drug Resist Date: 2014-12-23 Impact factor: 3.431
Authors: Diana Panesso; Paul J Planet; Lorena Diaz; Jean-Emmanuel Hugonnet; Truc T Tran; Apurva Narechania; Jose M Munita; Sandra Rincon; Lina P Carvajal; Jinnethe Reyes; Alejandra Londoño; Hannah Smith; Robert Sebra; Gintaras Deikus; George M Weinstock; Barbara E Murray; Flavia Rossi; Michel Arthur; Cesar A Arias Journal: Emerg Infect Dis Date: 2015-10 Impact factor: 6.883